



Crystallographic studies on the binding of selectively deuterated LLD- and LLL-substrate epimers by isopenicillin N synthase

Wei Ge^a, Ian J. Clifton^a, Jeanette E. Stok^{a,1}, Robert M. Adlington^a, Jack E. Baldwin^{a,*}, Peter J. Rutledge^{b,**}

^a Chemistry Research Laboratory, University of Oxford, Mansfield Rd., Oxford OX1 3TA, UK

^b School of Chemistry F11, The University of Sydney, NSW 2006, Australia

ARTICLE INFO

Article history:

Received 19 June 2010

Available online 13 July 2010

Keywords:

Antibiotics

Biosynthesis

Enzyme mechanism

Metalloenzymes

Non-heme iron oxidase

Penicillin

ABSTRACT

Isopenicillin N synthase (IPNS) is a non-heme iron(II) oxidase which catalyses the biosynthesis of isopenicillin N (IPN) from the tripeptide δ -L- α -aminoadipoyl-L-cysteiny-D-valine (LLD-ACV). Herein we report crystallographic studies to investigate the binding of a truncated LLL-substrate in the active site of IPNS. Two epimeric tripeptides have been prepared by solution phase peptide synthesis and crystallised with the enzyme. δ -L- α -Aminoadipoyl-L-cysteiny-D-2-amino-3,3-dideuteriobutyrate (LLD-ACD₂Ab) has the same configuration as the natural substrate LLD-ACV at each of its three stereocentres; its epimer δ -L- α -aminoadipoyl-L-cysteiny-L-2-amino-3,3-dideuteriobutyrate (LLL-ACD₂Ab) has the opposite configuration at its third amino acid. LLL-ACV has previously been shown to inhibit IPNS turnover of its substrate LLD-ACV; the all-protiated tripeptide δ -L- α -aminoadipoyl-L-cysteiny-D-2-aminobutyrate (LLD-ACAb) is a substrate for IPNS, being turned over to a mixture of penam and cepham products. Comparisons between the crystal structures of the IPNS:Fe(II):LLD-ACD₂Ab and IPNS:Fe(II):LLL-ACD₂Ab complexes offer a possible rationale for the previously observed inhibitory effects of LLL-ACV on IPNS activity.

© 2010 Elsevier Inc. All rights reserved.

1. Introduction

Isopenicillin N synthase (IPNS) is a non-heme iron(II) oxidase (NHIO) central to the biosynthesis of penicillin and cephalosporin antibiotics [1]. IPNS catalyses the oxidative bicyclisation of the linear tripeptide δ -L- α -aminoadipoyl-L-cysteiny-D-valine (LLD-ACV, **1**) to isopenicillin N (IPN, **2**) (Scheme 1A). This unusual transformation takes place in a single step via a putative iron(IV)-oxo intermediate [2,3], with one molecule of oxygen fully reduced to two molecules of water in the process [1]. It is broadly accepted that non-heme iron oxidases generate highly reactive iron(IV)-oxo (ferryl) species in their reaction cycles [4,5].

IPNS has been studied extensively over a number of years [1,6,7], on account of the unique transformation that it catalyses and the importance of this reaction to the industrial preparation

of β -lactam antibiotics for the clinic. The IPNS mechanism has been investigated primarily using solution-phase incubation experiments [6], solution-phase spectroscopy [7], and protein crystallography [8–14]. Incubation experiments in solution and *in crystallo* involve synthesizing analogues of ACV and incubating them with IPNS, then deducing mechanistic information by analysing the incubation products formed using either NMR for solution-phase experiments or crystallography for solid-phase experiments.

Reaction of the truncated analogue δ -(L- α -aminoadipoyl)-L-cysteiny-D- α -aminobutyrate (LLD-ACAb **3**) with IPNS gave three products: the epimeric C2-methyl penams α -methyl **4** and β -methyl **5**, plus cepham **6** (Scheme 1B) in a 1:7:3 product ratio (α -methyl penam: β -methyl penam:cepham) [15,16]. LLD-ACAb analogues in which the α -aminobutyrate residue is stereospecifically deuterated at its β -carbon have been incubated with IPNS, and intriguingly both isomers give the same β -methyl penam product **7** (Scheme 1B) [17]. In contrast IPN formation from ACV is highly stereoselective with respect to thiazolidine closure [18], presumably because the bulk of the isopropyl side-chain restricts its ability to rotate within the IPNS active site [2,19,20]. β -Methyl penam and cepham natural products similar to **5** and **6** but bearing a D- α -aminoadipoyl side-chain have been isolated from fermentations of *Streptomyces* ACC 13285 [21], and are presumably formed by IPNS-mediated cyclization of ACAb followed by side-chain epimerisation [1,21].

ACAb **3** lacks one methyl group relative to ACV **1** – the α -aminobutyrate residue presents an ethyl group in place of the isopropyl group of valine – and it has been postulated that the penam:


Abbreviations: AC6FV, δ - α -aminoadipoyl-cysteiny-3,3,3',3',3'-hexafluorovaline; ACA, δ - α -aminoadipoyl-cysteiny-alanine; ACD₂Ab, δ - α -aminoadipoyl-cysteiny-2-amino-3,3-dideuteriobutyrate; ACG, δ - α -aminoadipoyl-cysteiny-glycine; ACOMC, δ - α -aminoadipoyl-cysteine (1-carboxy-2-thiomethyl)ethyl ester; ACV, δ - α -aminoadipoyl-cysteiny-valine; IPN, isopenicillin N; IPNS, isopenicillin N synthase; NHIO, non-heme iron(II) oxidase.

* Corresponding author. Fax: +44 1865 285002.

** Corresponding author. Fax: +61 2 9351 3329.

E-mail addresses: jack.baldwin@chem.ox.ac.uk (J.E. Baldwin), peter.rutledge@sydney.edu.au (P.J. Rutledge).

¹ Present address: School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia.



Scheme 1. (A) The reaction of IPNS with its natural substrate LLD-ACV **1** to give IPN **2**; (B) IPNS-mediated turnover of LLD-ACAB **3** gives a mixture of two epimeric penams **4** and **5** plus the cepham **6**; (C) the selectively deuterated ACAB analogues used in this study $\text{LLD-ACd}_2\text{Ab}$ **10** and $\text{LLL-ACd}_2\text{Ab}$ **11**.

cepham product ratio observed with ACAB is controlled by the relative energy barriers to reaction of the iron(IV)-oxo intermediate with primary and secondary C–H bonds [22,23]. Compare the structures of the putative intermediates **8** and **9** formed in the reaction of IPNS with ACV **1** and ACAB **3** respectively (Scheme 1): the iron(II)-oxo moiety must distinguish between primary and tertiary C–H bonds in the first case, but between primary and secondary in the second. Crystallographic experiments and modelling studies based on the crystal structures have provided a structural rationale for the diminished product selectivity shown by IPNS in reaction with ACAB **3** and deuterated isotopomers [24].

The selectively di-deuterated substrate analogue $\delta\text{-L-}\alpha\text{-aminoadipoyl-L-cysteinyl-D-2-amino-3,3-dideuteriobutyrate}$ ($\text{LLD-ACd}_2\text{Ab}$ **10**) was conceived of as a mechanistic trap to probe the reaction of IPNS with ACAB **3** and isotopomers: by replacing both β -hydrogen atoms with deuterium it was envisaged that the resulting kinetic isotope effect would slow reaction at the β -position of ACAB, increasing reaction at the γ -carbon to probe cepham formation from these substrates. However attempts to trap intermediates in the reaction cycle of $\text{LLD-ACd}_2\text{Ab}$ **10** with IPNS *in crystallo* have not been successful, returning only complex mixtures of products at the enzyme active site. Thus attention has turned instead to the stereochemistry of the third amino acid in this truncated analogue, and we report herein crystal structures of IPNS in complex with the epimeric, truncated substrate analogues

$\text{LLD-ACd}_2\text{Ab}$ **10** and $\delta\text{-L-}\alpha\text{-aminoadipoyl-L-cysteinyl-L-2-amino-3,3-dideuteriobutyrate}$ ($\text{LLL-ACd}_2\text{Ab}$ **11**).

2. Materials and methods

2.1. Synthesis of $\text{LLD-ACd}_2\text{Ab}$ **10** and $\text{LLL-ACd}_2\text{Ab}$ **11**

Commercially available 1,1-dideutero ethanol **12** was treated with sodium hydride and *p*-toluenesulfonyl chloride to afford the corresponding *O-p*-toluenesulfonate, which was used to alkylate diethyl acetamidomalonate forming **13**. Acid-mediated deprotection and decarboxylation gave the free amino acid, which was protected as its benzhydryl ester **14** by reaction with *p*-toluenesulfonic acid and diphenyldiazomethane [25]. Coupling of **14** with known dipeptide **15** [20] was achieved using EDCI and HOBt in anhydrous dichloromethane to give the fully protected tripeptide **16** as a mixture of diastereoisomers [26]. Compound **16** was deprotected by heating in refluxing TFA for 30 min, in the presence of anisole as a cation scavenger [27]. The resultant crude mixture of the LLD- and LLL- tripeptides was purified by reversed phase HPLC (10 mM NH_4HCO_3 , Hypersil 5 μm C18 column, 250 \times 10 mm internal diameter, $\lambda = 254\text{ nm}$; 4 mL min^{-1}) to afford pure $\text{LLL-ACd}_2\text{Ab}$ **11** ($R_t = 11.3\text{ min}$) and $\text{LLD-ACd}_2\text{Ab}$ **10** ($R_t = 11.8\text{ min}$) in a 1:1 ratio. Stereochemical assignment of the two isomers was deduced by




Fig. 1. (A) The active site of anaerobic IPNS:Fe(II):LLD-ACd₂Ab complex; (B) the active site of anaerobic IPNS:Fe(II):LLL-ACd₂Ab complex; (C) overlay showing the relationship between the active site regions of the LLL-ACd₂Ab and LLD-ACd₂Ab complexes. A $2mF_o-DF_c$ map electron density map is shown in blue at 1σ in (A) and (B); the red sphere is iron (II).

analogy with related tripeptides, and confirmed by the X-ray crystal structures of their respective complexes with IPNS.

2.2. Crystallization experiments

Crystals of the IPNS:Fe(II):LLD-ACd₂Ab and IPNS:Fe(II):LLL-ACd₂Ab complexes were grown under anaerobic conditions as reported previously with minor modification [28,29]. Crystals suitable for structure determination were selected using a light

microscope, then removed from the anaerobic environment, exchanged into a cryoprotectant solution (1:1 mixture of well buffer: saturated lithium sulfate in 40% v/v glycerol solution), and flash-frozen in liquid nitrogen [28,29].

2.3. Data collection and structure determination

Data were collected at the Synchrotron Radiation Source (SRS), Daresbury, UK at 100 K, with temperature control achieved

through the use of an Oxford Cryosystems Cryostream. Data processing was carried out using MOSFLM [30] and programs from the CCP4 suite [31]. Refinement was undertaken with REFMAC5 [32], and the program O was used for model building [33]. Initial phases were generated by molecular replacement, using co-ordinates for the protein from the IPNS:Fe(II):ACV structure published previously [19], and manual rebuilding of protein side-chains was performed as necessary. Crystallographic coordinates and structure factors have been deposited in the Worldwide Protein Data Bank, accession numbers 2vbp for LLL-complex, 2wo7 for LLD. The colour (Fig. 1) was prepared using the program CCP4mg [34].


3. Results and discussion

It has been reported previously that LLL-ACV **17** – epimeric to the natural substrate LLD-ACV in the configuration of its third residue (valine) – is not turned over by IPNS, but inhibits turnover of

the natural substrate [35]. It was proposed at the time and in subsequent work with the LLL-configured substrates δ -L- α -amino adipoyl-L-cysteinyl-L-3,3,3,3',3',3'-hexafluorovaline (LLL-AC6FV **18**) [36] and δ -L- α -amino adipoyl-L-cysteine (1-(R)-carboxy-2-thiomethyl)ethyl ester (LLL-ACOMc **19**) [37] that LLL-substrates cannot be turned over by IPNS because they do not fit into the active site properly.

The novel substrate analogues LLD-ACd₂Ab **10** and LLL-ACd₂Ab **11** were prepared using solution phase peptide synthesis (Scheme 2) and crystallised with IPNS. Plate-shaped crystals of IPNS:-Fe(II):LLD-ACd₂Ab **10** and IPNS:Fe(II):LLL-ACd₂Ab **11** were obtained using standard conditions [28], and the structures of the IPNS:-Fe(II):LLD-ACd₂Ab and IPNS:Fe(II):LLL-ACd₂Ab complexes were solved to 2.50 Å and 1.50 Å resolution respectively (Fig. 1, Table 1).

The crystal structure of IPNS:Fe(II):LLD-ACd₂Ab (Fig. 1A) mirrors the IPNS:Fe(II):LLD-ACAb structure published previously, as is to be expected [24]. The substrate is bound in the active site by



Scheme 2. (A) Synthesis of tripeptides **10** and **11**. Reagents and conditions: (i) TsCl, NaH, rt, 68%; (ii) diethyl acetamidomalonate, Na, EtOH, 42%; (iii) HBr, 49%; (iv) TsOH, H₂O, then Ph₂CN₂, MeCN, 50%; (v) EDCL, HOBT, Et₃N, 48%; (vi) TFA, anisole, reversed phase HPLC, 20%; (B) 'all L' ACV analogues previously studied: LLL-ACV **17** [35], LLL-AC6FV **18**, [36] and LLL-ACOMc **19** [37].

Table 1

X-ray data collection and crystallographic statistics for IPNS:Fe(II):LLL-ACd₂Ab and IPNS:Fe(II):LLD-ACd₂Ab.

	IPNS:Fe(II):LLL-ACd ₂ Ab		IPNS:Fe(II):LLD-ACd ₂ Ab	
X-ray source	SRS, Daresbury, UK		SRS, Daresbury, UK	
Wavelength (Å)	1.488		1.488	
PDB acquisition code	2vbp		2wo7	
Resolution (Å)	1.50		2.50	
Space group	P2 ₁ 2 ₁ 2 ₁		P2 ₁ 2 ₁ 2 ₁	
Unit cell dimensions (a Å, b Å, c Å)	40.51, 74.34, 100.70		41.29, 74.76, 101.13	
Resolution shell (Å)	29.05–1.50	1.58–1.50	41.50–2.50	2.64–2.50
Total number of reflections	288 319	30 679	50 629	6815
Number of unique reflections	44 669	5345	11 384	1635
Completeness (%)	90.8	76.1	98.8	98.7
Average I/σ(I)	21.9	7.8	6.0	2.4
R _{merge} (%) ^a	5.3	20.9	20.8	58.9
R _{meas} (%) ^b	5.8	23.1	23.4	66.8
R _{pim} (%) ^c	2.2	9.6	10.5	30.7
R _{cryst} (%) ^d		22.3		18.9
R _{free} (%) ^e		26.8		25.7
RMS deviation ^f		0.021; 1.9		0.013; 1.432
Average B factors (Å ²) ^g		12.1; 14.8; 20.1; 27.1		17.1; 17.9; 18.0; 13.4
Number of water molecules		305		304

^a $R_{\text{merge}} = \sum_j \sum_h |I_{hj} - \langle I_h \rangle| / \sum_j \sum_h \langle I_h \rangle \times 100$.

^b $R_{\text{meas}} = \sum_{hkl} \sqrt{N/(N-1)} \sum_i |I_i(hkl) - \overline{I(hkl)}| / \sum_{hkl} \sum_i I_i(hkl) \times 100$ [38,39].

^c $R_{\text{pim}} = \sum_{hkl} \sqrt{1/(N-1)} \sum_i |I_i(hkl) - \overline{I(hkl)}| / \sum_{hkl} \sum_i I_i(hkl) \times 100$ [39].

^d $R_{\text{cryst}} = \sum ||F_{\text{obs}}| - |F_{\text{calc}}|| / \sum |F_{\text{obs}}| \times 100$.

^e R_{free} = based on 5% of the total reflections.

^f RMS deviation from ideality for bonds (followed by the value for angles).

^g Average B factors in order: main chain; side-chain; substrate and iron; solvent and sulfate.

coordination of the L-cysteiny l thiol to iron and a salt bridge between the L- α -aminoadipoyl carboxylate and Arg87. The dideutero-ethyl side-chain of the third residue (d_2 Ab) is oriented directly towards iron, into the putative oxygen binding site opposite Asp216. However the metal is hexacoordinate, with two water molecules coordinated to it, versus the single aquo ligand in the IPNS:Fe(II):LLD-ACV complex [19]: the smaller size of the aminobutyrate side-chain allows a water molecule to bind opposite Asp216, where the valinyl isopropyl group excludes water from this site when ACV **1** binds. It is important to note that LLD-ACAb and isotopomers are turned over by IPNS [15–17], so the water molecule bound opposite Asp216 does not tightly lock this site nor exclude oxygen binding and turnover.

The IPNS:Fe(II):LLD-AC d_2 Ab structure (Fig. 1B) is similar to the LLD-AC d_2 Ab complex around its L- α -aminoadipoyl and L-cysteiny l residues (the L- α -aminoadipoyl side-chain is tethered by the salt bridge to Arg87 and the L-cysteiny l sulfur to iron), but substantially different in the region of the third residue (d_2 Ab). The L- d_2 Ab side-chain points away from iron, into a region of space near Tyr189 that is occupied by water molecules in the IPNS:Fe(II):LLD-AC d_2 Ab and IPNS:Fe(II):LLD-ACV structures. The L- d_2 Ab carboxylate is oriented towards the metal, and hydrogen bonds to a water ligand in the iron binding site opposite Asp216. The dideutero-ethyl side-chain of L- d_2 Ab is comfortably accommodated in the region above Tyr189 that has previously been shown to accept the hexafluoro-isopropyl side-chain of **18** and the methylsulfide of **19** [36,37] even without the capacity for new hydrogen bonding or other interactions to compensate for the loss of hydrogen bonded water molecules usually present in this region.

Smaller tripeptides such as δ -L- α -aminoadipoyl-L-cysteiny l-glycine (LL-ACG) and δ -L- α -aminoadipoyl-L-cysteiny l-D-alanine (LLD-ACA) demonstrate a similar conformation when bound in the IPNS active site, with the carboxylate of their third residue oriented towards iron [40]. The smaller, less hydrophobic nature of these side-chains allows extra water molecules into the region opposite Asp216, and the glyciny l carboxylate of ACG is also tied by hydrogen bonding to a water ligand at the iron centre.

4. Conclusion

It has been shown previously that IPNS can tolerate great variation in the third residue of its substrate ACV **1**, reacting with a wide range of D-configured amino acids in the valinyl binding pocket [6]. Numerous analogues bearing a diverse range of side-chains in place of the valinyl isopropyl group are turned over by IPNS, including substrates that incorporate smaller side-chains (e.g. LL-ACG, LLD-ACA and LLD-ACAb discussed above), more sterically demanding alkyl chains (LLD-AC-isoleucine, LLD-AC-*allo*-isoleucine, LLD-AC- α -aminopentanoate), cyclopropyl groups (LLD-AC-cyclopropylalanine, LLD-AC-methylcyclopropylglycine), π -bonds (LLD-AC-vinylglycine, LLD-AC-dehydrovaline, LLD-AC-allyllycine) and heteroatoms (LLD-AC-O-methyl-*allo*-threonine, LLD-AC-S-methylcysteine) [6].

However LLL-configured analogues are not substrates for the enzyme, and can inhibit turnover [35]. The crystal structures of IPNS with LLD-AC d_2 Ab **10** and LLL-AC d_2 Ab **11** reported here demonstrate that for LLL-configured analogues like **11**, the side-chain of the third residue is oriented away from the active site metal, directed instead into a region of the protein above Tyr189. As a result the iron is unprotected: the binding site opposite Asp216 is open and coordinates an extra water ligand. This water molecule is held by hydrogen bonding to the terminal carboxylate of the tripeptide substrate, and the hydrogen bonding network appears robust enough to prevent oxygen from binding. Thus turnover is blocked before it can begin, and LLL-configured analogues inhibit turnover of LLD-substrates.

Acknowledgments

We thank Dr Annaleise Howard-Jones, Prof. Chris Schofield, Dr Victor Lee, Dr Zhihong Zhang, Dr Karl Harlos, Dr Jing He and the scientists at SRS daresbury for help and discussions.

References

- [1] J.E. Baldwin, C.J. Schofield, The biosynthesis of β -lactams, in: M.I. Page (Ed.), The Chemistry of β -Lactams, Blackie, Glasgow, 1992, pp. 1–78.
- [2] N.I. Burzlaff, P.J. Rutledge, I.J. Clifton, C.M.H. Hensgens, M. Pickford, R.M. Adlington, P.L. Roach, J.E. Baldwin, The reaction cycle of isopenicillin N synthase observed by X-ray diffraction, *Nature* 401 (1999) 721–724.
- [3] J.E. Baldwin, Recent advances in the chemistry of the β -lactam antibiotics, in: A.G. Brown, S.M. Roberts (Eds.), Special Publication No. 52, The Royal Society of Chemistry, London, 1985, pp. 62–85.
- [4] M. Costas, M.P. Mehn, M.P. Jensen, L. Que, Dioxygen activation at mononuclear nonheme iron active sites: enzymes, models, and intermediates, *Chem. Rev.* 104 (2004) 939–986.
- [5] P.C.A. Bruijninx, G. van Koten, R. Gebbink, Mononuclear non-heme iron enzymes with the 2-His-1-carboxylate facial triad: recent developments in enzymology and modeling studies, *Chem. Soc. Rev.* 37 (2008) 2716–2744.
- [6] J.E. Baldwin, M. Bradley, Isopenicillin N synthase: mechanistic studies, *Chem. Rev.* 90 (1990) 1079–1088.
- [7] R.D.G. Cooper, The enzymes involved in biosynthesis of penicillin and cephalosporin; their structure and function, *Bioorg. Med. Chem.* 1 (1993) 1–17.
- [8] P.L. Roach, I.J. Clifton, V. Fulop, K. Harlos, G.J. Barton, J. Hajdu, I. Andersson, C.J. Schofield, J.E. Baldwin, Crystal structure of isopenicillin N synthase is the first from a new structural family of enzymes, *Nature* 375 (1995) 700–704.
- [9] J.M. Ogle, I.J. Clifton, P.J. Rutledge, J.M. Elkins, N.I. Burzlaff, R.M. Adlington, P.L. Roach, J.E. Baldwin, Alternative oxidation by isopenicillin N synthase observed by X-ray diffraction, *Chem. Biol.* 8 (2001) 1231–1237.
- [10] A.R. Grummitt, P.J. Rutledge, I.J. Clifton, J.E. Baldwin, Active-site-mediated elimination of hydrogen fluoride from a fluorinated substrate analogue by isopenicillin N synthase, *Biochem. J.* 382 (2004) 659–666.
- [11] A. Daruzzaman, I.J. Clifton, R.M. Adlington, J.E. Baldwin, P.J. Rutledge, Unexpected oxidation of a depsipeptide substrate analogue in crystalline isopenicillin N synthase, *ChemBioChem* 7 (2006) 351–358.
- [12] A.R. Howard-Jones, J.M. Elkins, I.J. Clifton, P.L. Roach, R.M. Adlington, J.E. Baldwin, P.J. Rutledge, Interactions of isopenicillin N synthase with cyclopropyl-containing substrate analogues reveal new mechanistic insight, *Biochemistry* 46 (2007) 4755–4762.
- [13] W. Ge, I.J. Clifton, J.E. Stok, R.M. Adlington, J.E. Baldwin, P.J. Rutledge, Isopenicillin N synthase mediates thiolate oxidation to sulfonate in a depsipeptide substrate analogue: implications for oxygen binding and a link to nitrile hydratase?, *J. Am. Chem. Soc.* 130 (2008) 10096–10102.
- [14] W. Ge, I.J. Clifton, A.R. Howard-Jones, J.E. Stok, R.M. Adlington, J.E. Baldwin, P.J. Rutledge, Structural studies on the reaction of isopenicillin N synthase with a sterically demanding depsipeptide substrate analogue, *ChemBioChem* 10 (2009) 2025–2031.
- [15] G.A. Bahadur, J.E. Baldwin, J.J. Usher, E.P. Abraham, G.S. Jayatilake, R.L. White, Cell-free biosynthesis of penicillins – conversion of peptides into new β -lactam antibiotics, *J. Am. Chem. Soc.* 103 (1981) 7650–7651.
- [16] J.E. Baldwin, E.P. Abraham, R.M. Adlington, B. Chakravarti, A.E. Derome, J.A. Murphy, L.D. Field, N.B. Green, H.-H. Ting, J.J. Usher, Penicillin biosynthesis. Dual pathways from a modified substrate, *J. Chem. Soc. Chem. Commun.* (1983) 1317–1319.
- [17] J.E. Baldwin, E.P. Abraham, R.M. Adlington, J.A. Murphy, N.B. Green, H.-H. Ting, J.J. Usher, Penicillin biosynthesis. On the stereochemistry of carbon–sulphur bond formation with modified substrates, *J. Chem. Soc. Chem. Commun.* (1983) 1319–1320.
- [18] J.E. Baldwin, R.M. Adlington, B.P. Domayne-Hayman, H.-H. Ting, N.J. Turner, Stereospecificity of carbon–sulphur bond formation in penicillin biosynthesis, *J. Chem. Soc. Chem. Commun.* 11 (1986) 110–113.
- [19] P.L. Roach, I.J. Clifton, C.M.H. Hensgens, N. Shibata, C.J. Schofield, J. Hadju, J.E. Baldwin, Structure of isopenicillin N synthase complexed with substrate and the mechanism of penicillin formation, *Nature* 387 (1997) 827–830.
- [20] J.M. Elkins, P.J. Rutledge, N.I. Burzlaff, I.J. Clifton, R.M. Adlington, P.L. Roach, J.E. Baldwin, Crystallographic studies on the reaction of isopenicillin N synthase with an unsaturated substrate analogue, *Org. Biomol. Chem.* 1 (2003) 1455–1460.
- [21] D.C. Aldridge, D.M. Carr, D.H. Davies, A.J. Hudson, R.D. Nolan, J.P. Poyser, C.J. Strawson, Antibiotics 13285-A1 and 13285-A2 – novel cepham and penam metabolites from a *Streptomyces* species, *J. Chem. Soc. Chem. Commun.* (1985) 1513–1514.
- [22] J.M. Blackburn, J.D. Sutherland, J.E. Baldwin, A heuristic approach to the analysis of enzymic catalysis: reaction of δ -(L- α -aminoadipoyl)-L-cysteiny l-D- α -aminobutyrate and δ -(L- α -aminoadipoyl)-L-cysteiny l-D-allylglycine catalyzed by isopenicillin N synthase isozymes, *Biochemistry* 34 (1995) 7548–7562.
- [23] C.J. Rowe, C.P. Sharock, T.D. Claridge, J.D. Sutherland, Analysis of the conversion of δ -(L- α -aminoadipoyl)-L-cysteiny l-D- α -aminobutyrate by active-site mutants of *Aspergillus nidulans* isopenicillin N synthase, *Chem. Biol.* 5 (1998) 229–239.

- [24] A.J. Long, I.J. Clifton, P.L. Roach, J.E. Baldwin, C.J. Schofield, P.J. Rutledge, Structural studies on the reaction of isopenicillin N synthase with the substrate analogue δ -(L- α -aminoadipoyl)-L-cysteiny-D- α -aminobutyrate, *Biochem. J.* 372 (2003) 687–693.
- [25] S. Wolfe, M.G. Jokinen, Total synthesis of δ -(L- α -aminoadipoyl)-L-cysteiny-D-valine (ACV) a biosynthetic precursor of penicillins and cephalosporins, *Can. J. Chem.* 1979 (1978) 1388–1396.
- [26] J.C. Sheehan, J. Preston, P.A. Cruickshank, A rapid synthesis of oligopeptide derivatives without isolation of intermediates, *J. Am. Chem. Soc.* 87 (1965) 2492–2493.
- [27] M. Bodanzky, A. Bodanzky, The practice of peptide synthesis, in: K. Hafner, C.W. Rees, B.M. Trost, J.M. Lehn, P.V.R. Schleyer, R. Zahorchik (Eds.), *Reactivity and Structure Concepts in Organic Chemistry*, Springer-Verlag, Berlin, 1984, pp. 172–173.
- [28] P.L. Roach, I.J. Clifton, C.M.H. Hensgens, N. Shibata, A.J. Long, R.W. Strange, S.S. Hasnain, C.J. Schofield, J.E. Baldwin, J. Hajdu, Anaerobic crystallisation of an isopenicillin N synthase Fe(II) substrate complex demonstrated by X-ray studies, *Eur. J. Biochem.* 242 (1996) 736–740.
- [29] P.J. Rutledge, N.I. Burzlaff, J.M. Elkins, M. Pickford, J.E. Baldwin, P.L. Roach, The use of high-pressure oxygenation to promote reaction in enzyme crystals, *Anal. Biochem.* 308 (2002) 265–268.
- [30] A.G.W. Leslie, Integration of macromolecular diffraction data, *Acta Crystallogr. D* 55 (1999) 1696–1702.
- [31] Collaborative Crystallography Project Number 4, The CCP4 Suite: Programs for protein crystallography, *Acta Crystallogr. D* 50 (1994) 760–763.
- [32] G.N. Murshudov, A.A. Vagin, E.J. Dodson, Refinement of macromolecular structures by the maximum-likelihood method [Refmac], *Acta Crystallogr. D* 53 (1997) 240–255.
- [33] T.A. Jones, J.Y. Zou, S.W. Cowan, M. Kjeldgaard, Improved methods for building protein models in electron density maps and the location of errors in these models, *Acta Crystallogr. A* 47 (1991) 110–119.
- [34] L. Potterton, S. McNicholas, E. Krissinel, J. Gruber, K. Cowtan, P. Emsley, G.N. Murshudov, S. Cohen, A. Perrakis, M. Noble, Developments in the CCP4 molecular-graphics project, *Acta Crystallogr. D* 60 (2004) 2288–2294.
- [35] T. Konomi, S. Herchen, J.E. Baldwin, M. Yoshida, N.A. Hunt, A.L. Demain, Cell-free conversion of δ -(L- α -aminoadipoyl)-L-cysteiny-D-valine into an antibiotic with the properties of isopenicillin N in *Cephalosporium acremonium*, *Biochem. J.* 184 (1979) 427–430.
- [36] A.R. Howard-Jones, P.J. Rutledge, I.J. Clifton, R.M. Adlington, J.E. Baldwin, Unique binding of a non-natural ω -substrate by isopenicillin N synthase, *Biochem. Biophys. Res. Commun.* 336 (2005) 702–708.
- [37] W. Ge, I.J. Clifton, J.E. Stok, R.M. Adlington, J.E. Baldwin, P.J. Rutledge, The crystal structure of an ω -configured depsipeptide substrate analogue bound to isopenicillin N synthase, *Org. Biomol. Chem.* 8 (2010) 122–127.
- [38] K. Diederichs, P.A. Karplus, Improved R-factors for diffraction data analysis in macromolecular crystallography, *Nature Struct. Biol.* 4 (1997) 269–275.
- [39] M.S. Weiss, Global indicators of X-ray data quality, *J. Appl. Cryst.* 34 (2001) 130–135.
- [40] A.J. Long, I.J. Clifton, P.L. Roach, J.E. Baldwin, P.J. Rutledge, C.J. Schofield, Structural studies on the reaction of isopenicillin N synthase with the truncated substrate analogues δ -(L- α -aminoadipoyl)-L-cysteiny-glycine and δ -(L- α -aminoadipoyl)-L-cysteiny-D-alanine, *Biochemistry* 44 (2005) 6619–6628.